Long-term outcome of hematopoietic stem cell transplantation for IL2RG/JAK3 SCID: A cohort report

Blood

Volumn 129, Issue 15, 2017, Pages 2198-2201

  Abd Hamid, Intan Juliana ^a,b,c   Slatter, Mary A ^a,b   McKendrick, Fiona ^d   Pearce, Mark S ^a   Gennery, Andrew R ^a,b  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

^b Newcastle Upon Tyne Hospitals NHS Foundation Trust   (United Kingdom)

^c ADVANCED MEDICAL AND DENTAL INSTITUTE   (Malaysia)

^d NEWCASTLE UPON TYNE HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BUSULFAN; CD19 ANTIGEN; CD3 ANTIGEN; CYCLOPHOSPHAMIDE; FLUDARABINE; IMMUNOGLOBULIN; INTERLEUKIN 2 RECEPTOR GAMMA; JANUS KINASE 3; MELPHALAN; TREOSULFAN; IL2RG PROTEIN, HUMAN; JAK3 PROTEIN, HUMAN; LEUKOCYTE ANTIGEN;

ADOLESCENT; ADULT; ARTICLE; ASSESSMENT OF HUMANS; B LYMPHOCYTE; BONE MARROW CELL; BRONCHIECTASIS; CASE CONTROL STUDY; CD3+ T LYMPHOCYTE; CD4 LYMPHOCYTE COUNT; CD4+ T LYMPHOCYTE; CHILD; CHIMERA; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DATA COLLECTION METHOD; DONOR; FAMILY; FOLLOW UP; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; IMMUNOTHERAPY; LONG TERM CARE; LUNG FUNCTION; MYELOABLATIVE CONDITIONING; NATURAL KILLER CELL; OVERALL SURVIVAL; PEDSQL GENERIC CORE SCALE V4.0; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; QUALITY OF LIFE; RATING SCALE; REDUCED INTENSITY CONDITIONING; SCHOOL CHILD; SEVERE COMBINED IMMUNODEFICIENCY; SHORT STATURE; SURVIVAL RATE; TREATMENT OUTCOME; VERRUCA VULGARIS; ALLOGRAFT; DISEASE FREE SURVIVAL; FEMALE; GENETICS; HISTOCOMPATIBILITY; IMMUNOLOGY; MALE; MORTALITY; PRESCHOOL CHILD; RETROSPECTIVE STUDY; T LYMPHOCYTE; TIME FACTOR;

ADOLESCENT; ADULT; ALLOGRAFTS; ANTIGENS, CD; CHILD; CHILD, PRESCHOOL; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; INTERLEUKIN RECEPTOR COMMON GAMMA SUBUNIT; JANUS KINASE 3; MALE; QUALITY OF LIFE; RETROSPECTIVE STUDIES; SEVERE COMBINED IMMUNODEFICIENCY; SURVIVAL RATE; T-LYMPHOCYTES; TIME FACTORS; TRANSPLANTATION CHIMERA;

EID: 85019177554     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2016-11-748616     Document Type: Article

References (22)

1. Kwan A, Abraham RS, Currier R, et al. Newborn screening for severe combined immunodeficiency in 11 screening programs in the United States [published correction appears in JAMA. 2014; 312(20):2169]. JAMA. 2014;312(7):729-738.
2. Recher M, Berglund LJ, Avery DT, et al. IL-21 is the primary common g chain-binding cytokine required for human B-cell differentiation in vivo. Blood. 2011;118(26):6824-6835.
3. White H, Thrasher A, Veys P, Kinnon C, Gaspar HB. Intrinsic defects of B cell function in X-linked severe combined immunodeficiency. Eur J Immunol. 2000;30(3):732-737.
4. Fischer A, Griscelli C, Friedrich W, et al. Bone-marrow transplantation for immunodeficiencies and osteopetrosis: European survey, 1968-1985. Lancet. 1986;2(8515):1080-1084.
5. Antoine C, Müller S, Cant A, et al; European Group for Blood and Marrow Transplantation; European Society for Immunodeficiency. Long-term survival and transplantation of haemopoietic stem cells for immunodeficiencies: report of the European experience 1968-99. Lancet. 2003; 361(9357):553-560.
6. Buckley RH. Transplantation of hematopoietic stem cells in human severe combined immunodeficiency: longterm outcomes. Immunol Res. 2011;49(1-3):25-43.
7. Neven B, Leroy S, Decaluwe H, et al. Long-term outcome after hematopoietic stem cell transplantation of a single-center cohort of 90 patients with severe combined immunodeficiency. Blood. 2009;113(17):4114-4124.
8. Pai S-Y, Logan BR, Griffith LM, et al. Transplantation outcomes for severe combined immunodeficiency, 2000-2009. N Engl J Med. 2014;371(5):434-446.
9. Gennery AR, Slatter MA, Grandin L, et al; Inborn Errors Working Party of the European Group for Blood and Marrow Transplantation; European Society for Immunodeficiency. Transplantation of hematopoietic stem cells and long-term survival for primary immunodeficiencies in Europe: entering a new century, do we do better? J Allergy Clin Immunol. 2010;126(3):602-10.e1-11.
10. Bertrand Y, Landais P, Friedrich W, et al. Influence of severe combined immunodeficiency phenotype on the outcome of HLA non-identical, T-cell-depleted bone marrow transplantation: a retrospective European survey from the European group for bone marrow transplantation and the european society for immunodeficiency. J Pediatr. 1999;134(6):740-748.
11. Haddad E, Leroy S, Buckley RH. B-cell reconstitution for SCID: should a conditioning regimen be used in SCID treatment? J Allergy Clin Immunol. 2013;131(4):994-1000.
12. Buckley RH, Win CM, Moser BK, Parrott RE, Sajaroff E, Sarzotti-Kelsoe M. Post-transplantation B cell function in different molecular types of SCID. J Clin Immunol. 2013; 33(1):96-110.
13. Borghans JA, Bredius RG, Hazenberg MD, et al. Early determinants of long-term T-cell reconstitution after hematopoietic stem cell transplantation for severe combined immunodeficiency. Blood. 2006;108(2):763-769.
14. Cavazzana-Calvo M, Carlier F, Le Deist F, et al. Long-term T-cell reconstitution after hematopoietic stem-cell transplantation in primary T-cell-immunodeficient patients is associated with myeloid chimerism and possibly the primary disease phenotype. Blood. 2007;109(10): 4575-4581.
15. Slatter MA, Brigham K, Dickinson AM, et al. Long-term immune reconstitution after anti-CD52-treated or anti-CD34-treated hematopoietic stem cell transplantation for severe T-lymphocyte immunodeficiency. J Allergy Clin Immunol. 2008; 121(2):361-367.
16. Varni JW, Seid M, Kurtin PS. PedsQL 4.0: reliability and validity of the Pediatric Quality of Life Inventory version 4.0 generic core scales in healthy and patient populations. Med Care. 2001; 39(8):800-812.
17. Upton P, Eiser C, Cheung I, et al. Measurement properties of the UK-English version of the Pediatric Quality of Life Inventory 4.0 (PedsQL) generic core scales. Health Qual Life Outcomes. 2005;3(1):22.
18. Thrasher AJ, Hacein-Bey-Abina S, Gaspar HB, et al. Failure of SCID-X1 gene therapy in older patients. Blood. 2005;105(11):4255-4257.
19. Slatter MA, Rao K, Amrolia P, et al. Treosulfan-based conditioning regimens for hematopoietic stem cell transplantation in children with primary immunodeficiency: United Kingdom experience. Blood. 2011;117(16):4367-4375.
20. Slatter MA, Boztug H, Pötschger U, et al; EBMT Inborn Errors and Paediatric Diseases Working Parties. Treosulfan-based conditioning regimens for allogeneic haematopoietic stem cell transplantation in children with non-malignant diseases. Bone Marrow Transplant. 2015;50(12): 1536-1541.
21. Morillo-Gutierrez B, Beier R, Rao K, et al. Treosulfan-based conditioning for allogeneic HSCT in children with chronic granulomatous disease: a multicenter experience. Blood. 2016; 128(3):440-448.
22. Titman P, Pink E, Skucek E, et al. Cognitive and behavioral abnormalities in children after hematopoietic stem cell transplantation for severe congenital immunodeficiencies. Blood. 2008; 112(9):3907-3913.